HRP20211002T1 - 1,3-tiazol-2-il supstituirani benzamidi - Google Patents
1,3-tiazol-2-il supstituirani benzamidi Download PDFInfo
- Publication number
- HRP20211002T1 HRP20211002T1 HRP20211002TT HRP20211002T HRP20211002T1 HR P20211002 T1 HRP20211002 T1 HR P20211002T1 HR P20211002T T HRP20211002T T HR P20211002TT HR P20211002 T HRP20211002 T HR P20211002T HR P20211002 T1 HRP20211002 T1 HR P20211002T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- compound according
- disease
- disorders
- endometriosis
- Prior art date
Links
- -1 1,3-thiazol-2-yl Chemical group 0.000 title claims 2
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 33
- 230000036407 pain Effects 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 201000009273 Endometriosis Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000008764 nerve damage Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 3
- 208000004483 Dyspareunia Diseases 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- GTQPEQGDLVSFJO-CXAGYDPISA-N 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3R)-oxolan-3-yl]oxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound CC1=CN=C(S1)C=1C=C(C(=O)N[C@H](C)C=2C=NC(=NC=2)C(F)(F)F)C=C(C=1)O[C@H]1COCC1 GTQPEQGDLVSFJO-CXAGYDPISA-N 0.000 claims 2
- 208000025978 Athletic injury Diseases 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010051244 Dyschezia Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000005374 Poisoning Diseases 0.000 claims 2
- 208000010261 Small Fiber Neuropathy Diseases 0.000 claims 2
- 206010073928 Small fibre neuropathy Diseases 0.000 claims 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000020629 overactive bladder Diseases 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- 208000017692 primary erythermalgia Diseases 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- GTQPEQGDLVSFJO-DYVFJYSZSA-N 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3S)-oxolan-3-yl]oxy-N-[(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]benzamide Chemical compound CC1=CN=C(S1)C=1C=C(C(=O)N[C@H](C)C=2C=NC(=NC=2)C(F)(F)F)C=C(C=1)O[C@@H]1COCC1 GTQPEQGDLVSFJO-DYVFJYSZSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010004663 Biliary colic Diseases 0.000 claims 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 208000009079 Bronchial Spasm Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010068065 Burning mouth syndrome Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036018 Pollakiuria Diseases 0.000 claims 1
- 206010065347 Premenstrual pain Diseases 0.000 claims 1
- 206010036968 Prostatic pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010069645 Reduced bladder capacity Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000013116 chronic cough Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000035874 hyperreactivity Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 206010046494 urge incontinence Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Claims (16)
1. Spoj opće formule (I):
[image]
u kojem
R1 predstavlja C1-C4-alkil;
R2 predstavlja nesupstituirani tetrahidrofuran-3-il,
R3 predstavlja C1-C4-alkil;
A predstavlja CF3-pirimidinil;
ili njegov enantiomer, diastereomer, racemat, hidrat, solvat ili sol, ili njihova smjesa.
2. Spoj prema patentnom zahtjevu 1 opće formule (Ia):
[image]
3. Spoj prema patentnom zahtjevu 2, naznačen time što
R1 predstavlja metil ili etil.
4. Spoj prema bilo kojem od patentnih zahtjeva 2 do 3, naznačen time što
R3 predstavlja metil.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što A predstavlja 2-CF3-pirimidin-5-il.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što R2 predstavlja nesupstituirani (3R)-tetrahidrofuran-3-il, ili (3S)-tetrahidrofuran-3-il.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što R2 predstavlja nesupstituirani (3R)-tetrahidrofuran-3-il.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naime
3-(5-metil-1,3-tiazol-2-il)-5-[(3R)-tetrahidrofuran-3-iloksi]-N-{(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamid;
3-(5-metil-1,3-tiazol-2-il)-5-[(3S)-tetrahidrofuran-3-iloksi]-N-{(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamid.
9. Spoj prema patentnom zahtjevu 8, naime 3-(5-metil-1,3-tiazol-2-il)-5-[(3R)-tetrahidrofuran-3-iloksi]-N-{(1R)-1-[2-(trifluorometil)pirimidin-5-il]etil}benzamid.
10. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili enantiomer, dijastereomer, racemat, hidrat, solvat, njihovu farmaceutski prihvatljivu sol ili njihovu smjesu i farmaceutski prihvatljiv razrjeđivač ili nosač.
11. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1 do 9, ili enantiomera, dijastereomera, racemata, hidrata, solvata, njihove farmaceutski prihvatljive soli ili njihove smjese, za pripremu lijeka za profilaksu ili liječenje bolesti.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili enantiomer, dijastereomer, racemat, hidrat, solvat, ili njihova farmaceutski prihvatljiva sol, ili njihova smjesa, za uporabu u liječenju bolesti.
13. Spoj za uporabu prema patentnom zahtjevu 12, naznačen što je bolest, bolest odabrana iz skupine koju čine genitourinarni, gastrointestinalni, respiratorni ili s bolom povezane bolesti, stanja ili poremećaji; ginekološke bolesti, uključujući dismenoreju, dispareuniju i endometriozu; bol povezanu s endometriozom; simptome povezane s endometriozom, pri čemu su navedeni simptomi dismenoreja, dispareunija, disurija ili dishezija; tanja bolesti mokraćnog sustava povezana sa začepljenjem izlaza iz mokraćnog mjehura; stanja urinarne inkontinencije (smanjeni kapacitet mjehura, povećana učestalost mikcije, urgentna inkontinencija, stresna inkontinencija ili hiperreaktivnost mokraćnog mjehura); benigna hipertrofija prostate; hiperplazija prostate; prostatitis; hiperrefleksija detruzora; prekomjerno aktivni mokraćni mjehur i simptomi povezani s preaktivnim mokraćnim mjehurom, pri čemu su navedeni simptomi povećana učestalost mokrenja, nokturija, urinarna hitnost ili urgentna inkontinencija; zdjelična preosjetljivost; uretritis; prostatitis; prostatodinija; cistitis; idiopatska preosjetljivost mjehura; epilepsija; parcijalni i generalizirani napadaji; respiratorni poremećaji, uključujući kronični opstruktivni plućni poremećaj (KOPB), astmu, bronhospazam, kronični kašalj i slično; gastrointestinalni poremećaji, uključujući sindrom iritabilnog crijeva (IBS), upalnu bolest crijeva (IBD), bilijarne kolike i drugi žučni poremećaji, bubrežne kolike, IBS s dominantnim proljevom, gastroezofagealni refluks, gastrointestinalna distenzija, Crohnova bolest; Parkinsonova bolest; Alzheimerova bolest; infarkt miokarda; poremećaji lipida; i bolesti povezane s bolom odabrane iz skupine koju čine hiperalgezija, alodinija, funkcionalni poremećaji crijeva (sindrom iritabilnog crijeva), artritis (osteoartritis, reumatoidni artritis), opekline, migrena ili klaster glavobolje, ozljede živaca, neuritis, neuralgije, trovanje, ishemijska ozljeda, intersticijski cistitis, traumatska ozljeda živca, posttraumatske ozljede (uključujući prijelome i sportske ozljede), trigeminalna neuralgija, neuropatija malih vlakana, dijabetička neuropatija, kronični artritis i srodne neuralgije, neuropatija uzrokovana HIV-om i liječenjem HIV-a, pruritus.
14. Spoj za uporabu prema patentnom zahtjevu 12, naznačen time što je bolest povezana sa sindromima boli, uključujući akutnu, kroničnu, upalnu i neuropatsku bol.
15. Spoj za uporabu prema patentnom zahtjevu 14, naznačen time što je sindrom boli odabran iz skupine upalne boli, kirurške boli, visceralne boli, zubne boli, predmenstrualne boli, boli povezane s endometriozom, središnje boli, boli zbog sindroma peckanja usta, boli zbog opeklina, boli zbog migrene, klaster glavobolje, boli zbog ozljede živca, boli zbog neuritisa, neuralgije, boli zbog trovanja, boli zbog ishemijske ozljede, boli zbog intersticijskog cistitisa, boli zbog raka, boli zbog virusne, parazitske ili bakterijske infekcije, boli zbog traumatske ozljede živca, boli zbog posttraumatskih ozljeda, boli zbog prijeloma i sportskih ozljeda, boli zbog trigeminalne neuralgije, boli povezane s neuropatijom malih vlakana, boli povezane s dijabetičkom neuropatijom, kronične boli u donjem dijelu leđa, fantomske boli udova, sindroma boli u zdjelici, kronične boli u zdjelici, boli neuroma, složenog regionalnog sindroma boli, boli povezane s gastrointestinalnom distenzijom, kronične artritične boli i srodnih neuralgija, i boli povezane s rakom, boli povezane s kemoterapijom, neuropatije uzrokovane HIV-om i liječenjem HIV-a; i boli povezane s bolestima ili poremećajima odabranim iz skupine koju čine hiperalgezija, alodinija, funkcionalni poremećaji crijeva (sindrom iritabilnog crijeva) i artritis (osteoartritis, reumatoidni artritis).
16. Spoj za uporabu prema patentnom zahtjevu 13, naznačen time što je bolest bolest odabrana iz skupine ginekološke bolesti, dismenoreje, dispareunije, endometrioze, boli povezane s endometriozom, simptoma povezanih s endometriozom, disurije ili dishezije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196954 | 2014-12-09 | ||
| PCT/EP2015/078765 WO2016091776A1 (en) | 2014-12-09 | 2015-12-07 | 1,3-thiazol-2-yl substituted benzamides |
| EP15804824.9A EP3230281B1 (en) | 2014-12-09 | 2015-12-07 | 1,3-thiazol-2-yl substituted benzamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211002T1 true HRP20211002T1 (hr) | 2021-09-17 |
Family
ID=52015966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220371TT HRP20220371T1 (hr) | 2014-12-09 | 2015-12-07 | 1,3-tiazol-2-il supstituirani benzamidi |
| HRP20211002TT HRP20211002T1 (hr) | 2014-12-09 | 2021-06-24 | 1,3-tiazol-2-il supstituirani benzamidi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220371TT HRP20220371T1 (hr) | 2014-12-09 | 2015-12-07 | 1,3-tiazol-2-il supstituirani benzamidi |
Country Status (41)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3587417T (pt) * | 2014-12-09 | 2022-03-16 | Bayer Ag | Benzamidas substituídas por 1,3-tiazol-2-ilo |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN106588785A (zh) * | 2016-12-02 | 2017-04-26 | 山东吉田香料股份有限公司 | 一种乙酰基吡嗪的制备方法 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| SG11202011010YA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| MA52616A (fr) * | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| US11883407B2 (en) | 2018-10-05 | 2024-01-30 | Shionogi & Co., Ltd. | Medicament for the treatment of chronic cough |
| BR112021006889A2 (pt) * | 2018-10-10 | 2021-07-13 | Bellus Health Cough Inc. | método para tratar prurido em um mamífero |
| EP3930722A4 (en) * | 2019-02-25 | 2022-12-28 | Bellus Health Cough Inc. | TREATMENT WITH P2X3 MODULATORS |
| BR112021019987A2 (pt) * | 2019-04-05 | 2021-12-07 | Syngenta Crop Protection Ag | Compostos de diazina-amida pesticidamente ativos |
| MX2021012290A (es) * | 2019-04-11 | 2021-11-12 | Syngenta Crop Protection Ag | Compuestos de diazina-amida activos como pesticidas. |
| WO2020239951A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| CN114222741A (zh) | 2019-05-31 | 2022-03-22 | 奇斯药制品公司 | 作为p2x3抑制剂的吡啶并嘧啶类衍生物 |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
| AU2021282039A1 (en) * | 2020-05-25 | 2022-12-01 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Arylformamide compound and preparation method and medical use thereof |
| CN115884970A (zh) * | 2020-09-24 | 2023-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| CA3194087A1 (en) * | 2020-09-30 | 2022-04-07 | Xuejun Zhang | Benzamide compound and use thereof |
| CN116745284A (zh) | 2020-11-27 | 2023-09-12 | 奇斯药制品公司 | 作为p2x3抑制剂的酞嗪衍生物 |
| WO2022112491A1 (en) | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| MX2023005803A (es) | 2020-11-27 | 2023-05-29 | Chiesi Farm Spa | Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3). |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
| TW202404965A (zh) * | 2022-03-29 | 2024-02-01 | 大陸商人福醫藥集團股份公司 | Ｐ２ｘ３抑制劑化合物及其鹽、多晶型和用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745451B2 (en) | 2005-05-04 | 2010-06-29 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions |
| CA2654915C (en) | 2006-06-29 | 2015-07-28 | F.Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
| KR101165936B1 (ko) | 2006-11-09 | 2012-07-19 | 에프. 호프만-라 로슈 아게 | 티아졸 및 옥사졸-치환된 아릴아마이드 |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| US8653091B2 (en) | 2007-04-02 | 2014-02-18 | Evotec Ag | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| PL2139334T3 (pl) | 2007-04-17 | 2013-11-29 | Evotec Ag | Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| WO2008154601A1 (en) * | 2007-06-12 | 2008-12-18 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
| US8461185B2 (en) | 2007-10-31 | 2013-06-11 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| AU2008319308B2 (en) | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| DK2234976T3 (da) | 2007-12-17 | 2013-06-24 | Hoffmann La Roche | Nye pyrazol-substituerede arylamider |
| KR101405746B1 (ko) | 2007-12-17 | 2014-06-10 | 에프. 호프만-라 로슈 아게 | 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도 |
| BR122019016794B8 (pt) | 2007-12-17 | 2021-07-27 | Hoffmann La Roche | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune |
| WO2009077365A1 (en) | 2007-12-17 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazole-substituted arylamides |
| EP2262766B1 (en) * | 2008-02-29 | 2015-11-11 | Evotec AG | Amide compounds, compositions and uses thereof |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| MX2011004570A (es) * | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | Antagonistas del receptor p2x3 para el tratamiento del dolor. |
| AU2009328347B2 (en) | 2008-12-16 | 2016-06-09 | F. Hoffmann-La Roche Ag | Thiadiazole-substituted arylamides |
| JP5465782B2 (ja) | 2009-06-22 | 2014-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | 新規オキサゾロン及びピロリジノン置換アリールアミド |
| WO2010149578A2 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel biphenyl and phenyl-pyridine amides |
| WO2011088181A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| EP3998267A1 (en) | 2013-01-31 | 2022-05-18 | Bellus Health Cough Inc. | Imidazopyridine compounds and uses thereof |
| PT3587417T (pt) | 2014-12-09 | 2022-03-16 | Bayer Ag | Benzamidas substituídas por 1,3-tiazol-2-ilo |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| SG11202011010YA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
-
2015
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active IP Right Grant
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh active Active
- 2015-12-07 MX MX2020005909A patent/MX2020005909A/es unknown
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh active Active
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt active IP Right Grant
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en active Application Filing
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja active Active
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 MX MX2017007658A patent/MX2017007658A/es active IP Right Grant
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko active Application Filing
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en active Active
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh active
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh active
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
-
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
-
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja active Active
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
-
2019
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en active Active
-
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es unknown
-
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-06-24 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
-
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211002T1 (hr) | 1,3-tiazol-2-il supstituirani benzamidi | |
| CA2587149A1 (en) | Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds | |
| HRP20190815T1 (hr) | Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret) | |
| CY1121601T1 (el) | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα | |
| JP2016510033A5 (hr) | ||
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| EA201391730A1 (ru) | 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил) карбамимидоил)пиразин-2-карбоксамид | |
| JP2012515209A5 (hr) | ||
| EA201692356A1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| EA201291273A1 (ru) | Ингибиторы киназ, регулирующих апоптозный сигнал | |
| JP2017527578A5 (hr) | ||
| EA201490453A1 (ru) | Замещенные аналоги (e)-n-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| EA202092678A1 (ru) | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон | |
| JP2012515724A5 (hr) | ||
| PE20070593A1 (es) | Compuestos pirrolopirimidina como inhibidores de syk | |
| JP2017504635A5 (hr) | ||
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| RU2011134052A (ru) | Новые бензолсульфонамиды в качестве блокаторов кальциевых каналов | |
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| HRP20230798T1 (hr) | Inhibitori transglutaminaze 2 (tg2) | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EA201492283A1 (ru) | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) |